About US
Contact us
-
Mexico's Genomma lodges $834M bid for PrestigeA Mexican drugmaker aims to snap up the consumer products company Prestige Brands in a deal valued at almost $850 million. Genomma Lab, based in Mexico City, offered $16.60 per share for the U.S.-base2012/2/23
-
Abbott prevails as Supremes pass on J&J patent suitThe U.S. Supreme Court won't take up the Humira patent question. The high court's decision ends an ongoing squabble over Abbott Laboratories' ($ABT) tumor necrosis factor inhibitor, and whether it ste2012/2/23
-
FDA brings Sun's Doxil copy online to fix shortageFresh off its cobbled-together solution to a methotrexate shortage, the FDA says it's sewn up an alternate supply of the scarce cancer drug Doxil. The agency has approved a substitute for the Johnso2012/2/22
-
Pfizer reportedly weighing animal health IPOPfizer isn't saying much about its divestment plans. But that doesn't stop other people from talking. The latest? An IPO for the animal-health division, reported by the Financial Times. The FT's sourc2012/2/22
-
AZ sells discounted cancer drug directly to patientsDrugmakers are getting creative about capturing sales even after their products go off patent. And AstraZeneca ($AZN)is no exception: It's launching a direct-to-patients sales program for its breast c2012/2/21
-
Jury says J&J's Risperdal didn't cause plaintiff's diabetesA New Jersey jury has let Johnson & Johnson's ($JNJ)Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's doctor that diabet2012/2/21
-
NICE asks for more info on first-line Tarceva useThe U.K.'s cost-effectiveness watchdog has asked Roche ($RHHBY) for more information on Tarceva as a first-line treatment for non-small cell lung cancer. The National Institute for Health and Clini2012/2/20
-
Novartis to revamp Rasilez label with safety risksThe data on Rasilez's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links to strok2012/2/20
-
Wyeth puts $960M squeeze on Sun for Protonix launchSun Pharmaceuticals' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ($PFE) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's v2012/2/17
-
Leukemia drug shortage averted for now, FDA saysDisaster averted, say federal health officials. HHS Secretary Kathleen Sebelius told Congress yesterday that new supplies of the critically scarce drug methotrexate would be released in the coming day2012/2/17